DBV Technologies (NASDAQ:DBVT) Sets New 1-Year Low - Time to Sell?

Key Points

• DBV Technologies shares fell 2.1% to a new 52-week low of $9.64, well below the 50-day and 200-day moving averages of $13.03 and $16.30.
• Analysts remain broadly optimistic, with five Buy ratings and one Sell rating producing a consensus “Moderate Buy” rating and an average price target of $48.50.
• Institutional investors own 71.74% of the company’s stock, while DBV continues developing Viaskin Peanut, a wearable patch intended to treat peanut allergies through needle-free immunotherapy.

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) hit a new 52-week low on Thursday. The company traded as low as $9.64 and last traded at $9.77, with a volume of 535276 shares changing hands. The stock had previously closed at $9.98.

Analysts Set New Price Targets

A number of brokerages have issued reports on DBVT. Citigroup reaffirmed a "market outperform" rating on shares of DBV Technologies in a research report on Wednesday, September 30th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of DBV Technologies in a report on Thursday, September 10th. Citizens Jmp raised their target price on shares of DBV Technologies from $47.00 to $55.00 and gave the company a "market outperform" rating in a research note on Tuesday, June 30th. Weiss Ratings downgraded shares of DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, July 17th. Finally, HC Wainwright reissued a "buy" rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $48.50.

DBV Technologies Trading Down 2.1%

The stock has a market cap of $614.34 million, a price-to-earnings ratio of -2.78 and a beta of -1.04. The stock has a fifty day simple moving average of $13.03 and a 200-day simple moving average of $16.30.

Institutional Investors Weigh In On DBV Technologies

Institutional investors and hedge funds have recently made changes to their positions in the company. Vivo Capital LLC lifted its position in shares of DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock worth $55,726,000 after purchasing an additional 205,943 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of DBV Technologies in the first quarter valued at approximately $21,159,000. Perceptive Advisors LLC bought a new position in DBV Technologies in the 1st quarter worth approximately $20,146,000. Atika Capital Management LLC raised its position in DBV Technologies by 31.1% in the 1st quarter. Atika Capital Management LLC now owns 271,300 shares of the company's stock worth $5,667,000 after purchasing an additional 64,419 shares during the last quarter. Finally, Elmind Capital LP bought a new position in DBV Technologies in the 1st quarter worth approximately $5,536,000. Institutional investors and hedge funds own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's technology is designed to deliver therapeutic proteins through the skin without needles, with the goal of gradually modifying the immune system's response to specific allergens.

DBV Technologies' principal product candidate is Viaskin Peanut, an investigational epicutaneous immunotherapy designed to expose patients to small amounts of peanut protein through a wearable patch.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.